For Payors

A NEW STANDARD OF CARE

Faster tumor analysis controls testing costs

Pathologic grading is subjective and ultimately of little help in patient care planning. Fifty percent of patient tumors are categorized grade 2, forcing oncologists to rely on further testing. But large percentages of patients with grade 2 and 3 tumors are eventually discovered to be low risk and could have been spared the time and costs of gene expression testing.

LEARN MORE. MORE QUICKLY.

Patients Get on the Right Care Program Faster

PreciseBreastTM is the only solution that offers a faster, less expensive and, in some cases, more accurate alternative to gene expression testing for predicting the likelihood of tumor recurrence.

The Underlying Problem

Tumor analysis is not accurate enough for many patients

Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading. As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.

50%

of breast tumors are categorized as Grade 2*

65%

Intra-observer variations in grading results***

56%

of Grade 3 tumors are low risk**

22%

of Grade 2 tumors are high risk**

78%

of Grade 2 tumors are low risk**

1 in 8 women will be diagnosed with breast cancer in their lifetime.

*Sparano, New England Journal of Medicine. 2018
**Based on a retrospective longitudinal study of more than 2,000 cancer cases. Fernandez, G., Prastawa, M., Madduri, A.S. et al. Breast Cancer Research 2022’.
***Paik, New England Journal of Medicine, 2004

Precision matters

Using PreciseBreastTM as well as gene expression or visual pathologic analysis delivers benefits for patients, physicians, and payors.

Data to drive precise reporting of tumor recurrence risk

Faster results lessen anxiety for patients

Lower overall costs for treatment and testing

Availability to 100% of eligible patients

our process

The clinical pathway

PreciseBreast is designed specifically to improve the multidisciplinary team’s workflow, providing a complement to pathological tumor grading and gene expression testing.

Screening / Detection

Biopsy & Diagnosis

Resection

Tumor Grading

Tumor Staging

Gene-Expression Testing

Care Planning

who we serve

PreciseStories

The results of slow or unavailable gene-expression testing can impact patients and their anxiety levels during a critical time in their lives. These are their stories of how PreciseBreast might have made a difference.

FAQ’s

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare

This is the first question in the FAQ section for Surgeons

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here

This is the second question in the FAQ section for Surgeons

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here

This is the third question in the FAQ section for Surgeons

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here

This is the fourth question in the FAQ section for Surgeons

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere eros dolor interdum nulla, ut commodo diam liber eros dolor interdum nulla, ut commodo. Learn more here

Let us show you the difference Visible Intelligence makes

Contact us today to learn more about PreciseBreast.

Get in Touch